-
Research reveals 72% of women would consider starting weight loss medications in the New Year
-
Difficulty maintaining a consistent diet was cited as the top barrier to weight loss
As the new year ushered in the annual opportunity to set new goals for the year ahead, weight loss and getting fit will almost certainly have featured high on the list – although these are commonly known to be the unsustainable resolutions that don’t continue past January and the hastily joined gym memberships taken out in a hurry often sit unused for the remainder of the year.
However, 2025 may be different.
2024 saw a rapid adoption and acceptance of GLP-1s medications as an effective and trusted method of weight loss, with recent research from digital weight loss platform Juniper, revealing that almost three quarters (72%) of women are now considering turning to GLP-1 medications to help them in their weight loss journey.
Surveying over 1,000 UK women, the research found that 86% of respondents have tried multiple diet and weight loss programmes to lose weight with over half (55%) having previously committed to one or two different methods and a fifth (22%) admitting to trialling three to five different weight-loss methods. However, despite ambitions, many face barriers to their weight loss journeys. Difficulty maintaining a consistent diet (30%) was noted as the top hurdle, followed by a lack of time for regular exercise (16%) and mental health or motivational challenges (15%).
With many using the New Year to commit to new goals, a quarter (24%) of women noted that they have set a New Year’s resolution related to weight loss or fitness over five times and a third (33%) one to two times. While a common resolution, with so many diets and fitness regimes available it’s not always easy for individuals to choose the most effective method for their goals.
While interested in trying GLP-1 medications, women have experienced blockers when trying to attain access to these medications including:
-
The cost of the medication: 42%
-
Doubts on whether it will work for them and their weight loss: 37%
-
Worried about the side effects: 36%
-
Worried about weight gain once the medication ends: 33%
-
Worried about the stigma of using medication for weight loss: 31%
-
The difficulty of getting a GP appointment to discuss options: 25%
While access and stigma continue to be issues, these worries also highlight the importance of wrap-around care with GLP-1 medications. Better access and availability to speak with weight specialists who can provide information about GLP-1s and their impact alongside medical support and coaching programmes focused on lifestyle and behaviour changes is crucial.
Editor of Healthcare Newsdesk and Wellbeing News, Lisa Baker, is a firm advocate for weight loss medication. Lisa explains:
“This time last year, I was diagnosed with pneumonia after nearly being hospitalised on Christmas Eve. I’d actually been ill since November. Weight 17st 10lbs and only 5ft tall, my body was already struggling and the illness knocked me for six.
“I started a new diet practically every week but couldn’t sustain it for long, sugar cravings and junk food were patterns that I found very hard to break, I would also start to exercise but arthritis flare ups and work patterns didn’t help.
“Once I had recovered sufficiently from the pneumonia (which took a few more months) I decided I needed to urgently tackle my health no matter what the cost. Unable to get an appointment with my GP, I underwent an online consultation for Mounjaro and I haven’t looked back.
“I am now 11 stone 13lbs, with just over two stone left to lose to reach a healthy BMI. Exercise is now much easier, with less strain on my joints, less pain and I have far more healthy eating patterns because food noise and cravings no longer disrupt my eating patterns. My biggest side effect is not craving food any more, along with tiredness for the day after the jab. It’s the best decision I have made and the provider has liaised directly with my GP throughout my treatment, so I have felt safe and supported throughout.”
Kevin Joshua, Clinical Lead at Juniper commented, “It’s no wonder that word is spreading about GLP-1s with the medicines having demonstrated remarkable efficacy in treating obesity with patients already seeing incredible results. This New Year I would expect that we will start to see people considering very different approaches to their weight loss and fitness goals than they have taken in the past.
“GLP-1s are giving individuals new leases of life, however, it’s vital that to ensure they continue to do so, we improve access to the medication and tackle the blockers many are facing in accessing them. Increased use on the NHS needs to go hand in hand with more education and wrap-around care to ensure that those in need of GLP-1s feel informed and supported through their journey.”
.
